Lilly wins EU backing for copy of Sanofi's top insulin Lantus

June 27, 2014 12:51 PM

13 0

LONDON (Reuters) - European regulators have for the first time recommended approval of a copycat insulin for diabetics, posing a threat to French drugmaker Sanofi SASY.PA whose top-selling Lantus is now set to face a cheaper rival in 2015.

The new drug, known as Abasria, is made by U.S. rival Eli Lilly LLY.N, which has developed it as a so-called biosimilar version of Sanofi's $8 billion-a-year Lantus, or insulin glargine.

Read more

To category page